MCM
NYMX

MAI Capital Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

MAI Capital Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,000
Closed -$44K – 982
2022
Q1 		$44K Buy
+35,000
New +$54K ﹤0.01% 881

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

MAI Capital Management's NYMX Position: Q2 2022 in Review

MAI Capital Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2022, closing a stake of 35,000 shares — an estimated $44K sold.

MAI Capital Management first reported a position in NYMX in Q1 2022 and held it in 1 quarter. The position peaked at $44K in Q1 2022. 39 funds tracked by Wall St. Rank hold NYMX as of Q2 2022.

  • MAI Capital Management reported no remaining Nymox Pharmaceutical Corp position as of Q2 2022 after selling out during the quarter.
  • MAI Capital Management sold 35,000 Nymox Pharmaceutical Corp shares in Q2 2022, an estimated $44K.
  • MAI Capital Management first reported a position in Nymox Pharmaceutical Corp in Q1 2022 and held it in 1 quarter.
  • MAI Capital Management's Nymox Pharmaceutical Corp position peaked at $44K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2022.

Based on MAI Capital Management's 13F filing for Q2 2022, filed 19 Jul 2022.